Key Developments: DexCom, Inc. (DXCM.O)
8.83USD
9 Feb 2010
$-0.03 (-0.34%)
$8.86
$9.00
$9.06
$8.72
248,584
420,809
$10.20
$3.18
Latest Key Developments
DexCom, Inc. Announces Sale Of 3.5 Million Shares Of Common Stock
DexCom, Inc. announced the sale of 3.5 million shares of its common stock pursuant to an underwriting agreement with Canaccord Adams acting as the sole bookrunner. The last reported sale price of our common stock as reported by the Nasdaq Global Market on January 14, 2010 was $9.22 per share. The Company expects to use the net proceeds from the sale of the shares for working capital and general corporate purposes. Closing of the offering is expected to occur on or about January 21, 2010, subject to customary closing conditions. In addition, the Company has granted the underwriters a 30 day option to purchase up to an additional 525,000 shares of common stock to cover over allotments, if any.
Edwards Lifesciences Corporation and DexCom, Inc. Announce Receipt Of CE Mark For Glucose Monitoring System
Edwards Lifesciences Corporation and DexCom, Inc. announced the receipt of CE Mark for an automatic glucose monitoring system. Edwards and DexCom co-developed this new system, which is indicated for automatic, real-time monitoring and trending of blood glucose concentration in critically ill adults in the hospital environment. This CE Mark allows for commercialization of the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark. Market evaluations of a first generation product are expected to begin in a limited number of European sites before the end of the year. Studies have shown that hospitalized patients can be at a higher risk of infection and other complications if their blood glucose level is elevated for prolonged periods. Currently, clinicians manage patients' glucose levels by manually obtaining intermittent samples over various periods of time. Methods for obtaining blood samples can be labor intensive and may not provide complete information about a patient's glucose status. This glucose monitoring system will perform multiple automatic readings per hour that may provide a new level of trending insight designed to enable clinicians to effectively implement glycemic control.
DexCom, Inc. Receives CE Mark Approval for SEVEN PLUS Continuous Glucose Monitoring System
DexCom, Inc. announced that it has received CE Mark (Conformité Européene) approval for the SEVEN PLUS continuous glucose monitoring system, enabling commercialization of the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark.
DexCom, Inc. Amends Collaboration Pact With Edwards Lifesciences Corporation-DJ
Dow Jones reported that DexCom, Inc. said Edwards Lifesciences Corporation's development funding obligation to DexCom, Inc. under a collaboration agreement will be reduced by $1.5 million through an amendment to the pact. The San Diego medical-device company said under the pact, DexCom's development obligations include, among other things, completion of clinical trials for the first-generation product under development to support an application for regulatory approval, according to a Securities and Exchange Commission filing. DexCom, Inc. said the reduction of $1.5 million is the amount estimated to complete the relevant portion of the clinical trials.
DexCom, Inc. Announces Closing of Public Offering of Common Stock
DexCom, Inc. announced public offering of 15,844,000 shares of its common stock at a price of $3.00 per share. In addition, Terrance H. Gregg, DexCom`s President and Chief Executive Officer, also purchased 150,000 additional shares of common stock in this offering at a price per share of $3.12, which represents the last reported bid price on the NASDAQ Global Market of DexCom`s common stock on January 29, 2009. The gross proceeds to DexCom, before expenses, from the sale of the shares were $48 million. Piper Jaffray & Co. acted as sole manager for the offering.
DexCom, Inc. Announces Pricing of Public Offering of Common Stock
DexCom, Inc. announced the offering of 15,844,000 shares of its common stock at a price to the public of $3.00 per share. Terrance H. Gregg, DexCom's President and Chief Executive Officer, is also purchasing 150,000 additional shares of common stock in this offering at a price per share of $3.12, which represents the last reported bid price on the NASDAQ Global Market of DexCom's common stock on January 29, 2009. The gross proceeds to DexCom, before expenses, from the sale of shares are expected to be $48 million. The closing of the offering is expected to take place on February 4, 2009. Piper Jaffray & Co. acted as sole manager for the offering.
DexCom, Inc. Announces Public Offering of Shares of Common Stock
DexCom, Inc. announced that it intends to offer shares of its common stock in a public offering pursuant to an effective shelf registration statement. All of the shares of common stock will be offered by the Company. Piper Jaffray & Co. will act as underwriter. A shelf registration statement relating to the shares was originally filed with the Securities and Exchange Commission on November 14, 2008 and has since been declared effective. The offering will be made pursuant to a prospectus supplement to the prospectus contained in the shelf registration statement, which prospectus supplement will be filed with the SEC.
DexCom, Inc. Amends Joint Development Agreement With Animas Corporation To Bring Continuous Glucose Monitoring Enabled Insulin Pumps Outside U.S.
DexCom, Inc. announced the amendment of its joint development agreement with Animas Corporation to extend outside the U.S. This revised agreement gives Animas exclusive rights to DexCom CGM technology, now and in the future, for integration into Animas insulin pumps outside the U.S. Animas also retains the non exclusive right to develop and market CGM-enabled ambulatory insulin pumps within the United States. Under the terms of the agreement, Animas will receive an exclusive right to develop and market CGM-enabled ambulatory insulin delivery systems outside the U.S. Animas will pay DexCom a one time $5 million milestone payment upon the first regulatory body approval outside the U.S. for the new system. In addition, Animas will contribute $300,000 to offset a portion of DexCom's development expenses for the new system. The parties have also entered into a commercialization agreement under which Animas will obtain distribution rights for DexCom sensors and transmitters to users of the integrated system and will pay a royalty to DexCom for each CGM-enabled pump sold outside the U.S. The initial term of the development agreement is three years and the initial term of the commercialization agreement is three years from the first commercial product launch. The initial product will be based on Animas's advanced pump technology and DexCom's SEVEN continuous glucose monitoring system.
DexCom, Inc. Receives CE Mark Approval For SEVEN Continuous Glucose Monitoring System
DexCom, Inc. announced that it has received CE Mark (Conformité Européene) approval for the SEVEN, its seven day continuous glucose monitoring system, enabling commercialization of the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark.
Edwards Lifesciences Corporation And DexCom, Inc. To Develop Continuous Glucose Monitoring Products For Hospital Market
Edwards Lifesciences Corporation and DexCom, Inc., a developer and marketer of home-based continuous glucose monitoring systems for patients with diabetes, announced that they have entered into a definitive collaboration agreement to develop products for continuously monitoring blood glucose levels in patients hospitalized for a variety of conditions. The agreement provides Edwards with an exclusive license to all of DexCom's applicable intellectual property. Under the terms of the agreement, Edwards will pay DexCom an upfront licensing and collaboration fee of $13 million in cash, resulting in a nonrecurring charge for Edwards in the fourth quarter of 2008. Edwards will also pay up to $24 million over the next three years in product development costs and regulatory approval milestones.
Test of "artificial pancreas" offers diabetes hope
LONDON (Reuters) - Scientists have used an "artificial pancreas" system of pumps and monitors to improve blood sugar control in diabetes patients in the first study to show the new device works better than conventional treatment.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
